Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DNA Halo
- Development stage
- Unknown
- Lead developer
- Cora
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DNA Halo is an orally administered nutraceutical antioxidant supplement developed by Cora for protection against oxidative and radiation-associated DNA damage and for general antioxidant wellness support. It is a proprietary multi-ingredient small-molecule antioxidant complex containing quercetin, vitamin C, vitamin E, coenzyme Q10, alpha-lipoic acid, astaxanthin, zeaxanthin, folic acid, vitamin B12, and selenium. The intended mechanism is scavenging reactive oxygen species and free radicals to reduce oxidative injury to nuclear and mitochondrial DNA, including damage associated with ionizing radiation exposure such as medical imaging or occupational exposure.
- Brand names
- DNA Halo
- Other names
- Halo
Beyond the preview
Go deeper on DNA Halo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DNA Halo.